BCL2 and adult T-cell leukemia/lymphoma: Thus, IKK inhibition not only disrupts oncogenic NF-κB signaling but also undermines BCL–2–dependent survival mechanisms, providing a promising targeted therapeutic strategy for overcoming the intrinsic resistance of ATLL to conventional treatments.